Neutrophils (polymorphonuclear neutrophils, PMNs) are one of the first inflammatory cells to be recruited in response to cell damage, infectious agents, and allergens (1) (2) (3) . Although the role of PMNs in the pathogenesis of asthma has not been defined, they have been described in the human bronchial wall of both allergic and nonallergic asthmatic subjects (4) . Previous studies have shown that allergen challenge in humans as well as in animal models causes an increase in the number of PMNs within the lung that has been associated with the presence of chemokines in peripheral blood and bronchoalveolar lavage fluid (5-11).
Moreover, peripheral blood PMNs are activated during active asthma (12) , after exercise-induced bronchospasm (9) , and during both early and late asthmatic reactions induced by allergen (13) . These cells also have the capacity to synthesize and release various mediators, such as cytotoxic compounds and cytokines (14) , suggesting that PMNs could be involved in events central in the pathogenesis of asthma including bronchoconstriction, tissue damage, and chronic airway inflammation (13) .
IgE binding structures play a pivotal role in many pathophysiological mechanisms of atopic diseases such as asthma. So far, two types of IgE receptors have been demonstrated in human PMNs: galactin 3 (Mac-2/εBP) and the low-affinity receptor for IgE (FcεRII/CD23) (15) (16) . Besides these receptors, the high-affinity receptor for IgE (FcεRI) is a key structure involved in immediate allergic manifestations. Initially, it was described on mast cells and basophils (17) (18) (19) (20) , but more recently on other cell types, including eosinophils, and has been correlated with atopic disease (21) (22) (23) (24) (25) (26) . However, whether human PMNs express the FcεRI has not been determined. To improve our understanding of the pathophysiologic role of PMNs in atopic disease, we examined this prospect. Our study shows that human PMNs from asthmatic patients express functional FcεRI receptor and provide a potential mechanism by which these cells may contribute to the manifestation of allergic disorders.
MATERIALS AND METHODS

Reagents and antibodies
Murine anti-human FcεRI␣ chain monoclonal antibody mAb-15 (21) and affinity-purified rabbit polyclonal antihuman FcεRI␤ chain (976, raised against a peptide representing amino acids 24 -39 of human FcεRI␤ chain) were kindly donated by Dr. J. P. Kinet (Harvard Medical School, Boston, Mass.). Murine anti-FcεRI␣ chain mAb mAbCRA2 (mouse IgG1), which recognizes the IgE binding site, was described previously (27) . FITC-labeled goat anti-mouse IgG was purchased from Santa Cruz Biotechnology (Santa Cruz, Calif.). FITC-labeled mouse anti-human CD16 mAb (Clone 3G8, IgG1), extravidin-FITC, affinity-purified human IgG, goat anti-mouse IgG(Fab)Ј 2 , and IgG1 isotype control mAb (clone MOPC21, IgG1) were obtained from Sigma Chemical Co. (Oakville, Ontario). H. Gould (Randall Royal King Institute, London, U.K.) kindly donated IgE Fc fragment. Azide-free IgE Fc fragment was biotinylated using biotin succinimide (Biosearch, Saint Rafael, Quebec, Canada); excess biotin was then removed by dialyses against PBS. Mouse anti-human elastase mAb, alkaline phosphatase anti-alkaline phosphatase (APAAP), rabbit anti-mouse IgG, streptavidin phosphatase alkaline, swine anti-rabbit F(ab)Ј 2 FITC, FITC-labeled mouse IgG1 isotype control mAb, and biotin-labeled swine antirabbit were from Dako (Dakopatt, Denmark). Biotin-labeled horse anti-mouse IgG was from Vector Laboratories (Burlingame, Calif.). Anti-CD16 mAb immunomagnetic beads were from Miltenyi Biotec (Auburn, Calif.). Unless stated otherwise, all other reagents were obtained from Sigma.
Subjects
This study was approved by the Ethics Committee of the Montreal Chest Hospital, Montreal, Quebec. Eighteen mild asthmatic patients, as defined by the American Thoracic Society, were included in this study (28) . Eighteen nonatopic, nonasthmatic controls with negative skin tests and normal spirometry were also studied. Patients had not received inhaled or systemic corticosteroids in the last 3 months and were not receiving any medication other than ␤ agonists. Subjects who had upper respiratory tract infection within the last month were excluded from the study. Bronchoscopy was performed on asthmatic subjects as described previously (4).
Human PMN purification
Blood was taken after informed consent and collected into heparinized tubes. Human PMNs were purified as described previously (29) . In brief, blood was diluted with Ca 2ϩ /Mg 2ϩ -free PBS, then overlaid onto a Ficoll-Paque gradient and centrifuged at 400 g for 20 min. The granulocyte-rich fraction was then mixed with dextran 70 (4.5%) and the red blood cells (RBCs) were allowed to sediment for 30 min at room temperature. The supernatant was collected and centrifuged for 10 min at 400 g to recover the granulocytes. The residual RBCs were lysed with hypotonic saline. The granulocytes were then incubated with anti-CD16-coated microbeads for 30 min at 4°C and the contaminating cells were eluted by washing the cells with PBS/1% BSA through a MACS column. PMNs with a purity of 98% Ϯ 1.4% were obtained using this technique as determined by staining cytospins with Diff-Quick (Fisher Scientific, Pittsburgh, Pa.). The viability of the cells was Ͼ98% as assessed by trypan blue dye exclusion.
Cell line and culture conditions
The human cell line HL-60 clone 15 was provided from the American Tissue Culture Collection (ATCC) (Rockville, Md.). Cells were cultured at 37°C in humidified 5% CO 2 in RPMI 1640 medium supplemented with 10% heat-inactivated FCS and antibiotics (100 U/ml penicillin and 100 g/ml streptomycin). Differentiation toward the eosinophils or neutrophils was performed as described previously (30) . Cells were grown in RPMI 1640, 10% FCS in the presence of butyric acid (0.3 mM) or DMSO (1.25% V/V) for 7 days to generate eosinophils or neutrophils, respectively.
Northern blot analysis
Probe: 572 bp of the FcεRI␣ chain cDNA within the coding region was made by RT-PCR using specific primers (␣1 and ␣2) of the FcεRI␣ chain (22) . After enzyme digestion analysis and subcloning in pBluescript vector (Stratagene, La Jolla, Calif.), the probe was confirmed by sequencing. The vector was linearized with appropriate digestion enzyme to recover the FcεRI␣ chain cDNA. Total RNA from highly purified PMNs was extracted using Trizol as recommended by the supplier (Gibco BRL, Burlington, Canada). Equal amounts of total RNA (10 g) were separated by electrophoresis on 1.2% agarose formaldehyde denaturing gel (31) and transferred to nylon membranes (Amersham Int., Burckinghamshire, U.K.). The blots were prehybridized for 2 h at 42°C in hybridization solution (40% formamide, 10% dextran sulfate, 4% SSC, 20 mmol/Tris-HCl pH 7.4, 1ϫ Denhardt's solution, 50 g/ml denatured salmon sperm DNA, and 0.1% SDS). Hybridization was performed with human FcεRI␣ chain cDNA probe labeled with 32 P-dCTP by random hexamer priming (Amersham) for 18 h at 42°C. The blots were washed at high stringency conditions: three times at room temperature in 2ϫ SSC, 0.05% SDS and twice at 55°C in 0.1ϫ SSC, 0.05% SDS for 30 min each. After hybridization, blots were washed, dried, and exposed to Kodak XAR film with an intensifying screen at Ϫ70°C.
RT-PCR analysis
Reverse transcription (RT) was performed by using 2 g of total RNA of PMNs obtained from each patient in a firststrand cDNA synthesis reaction with Super Script reverse transcriptase as recommended by the supplier (GibcoBRL). PCR was performed by adding 1 l of the RT product into 50 l of total volume reaction containing 1ϫ buffer; 200 mol of each dNTPs; 20 pmol of each oligonucleotide primer and 0.2 unit of Ampli-Taq polymerase (Gibco-BRL). Oligonucleotides specific for ␣, ␤ and ␥ sequences on either side of a splice junction were used in the PCR reaction to preclude amplification of possible contaminating genomic DNA. Oligonucleotide primers were designed based on the published sequences (20) . The FcεRI ␣ chain oligonucleotides were ␣1: 5ЈTACAGTAATGTTGAGGGGCTCAG3Ј; ␣2: 5ЈCTGTTCT-TCGCTCCAGATGGCGTT3Ј; internal primer or ␣3: 5ЈCCT-GTACACATCCCAGTTCCTCCAACCAT3Ј. The FcεRI␤ chain primers were 5Јprimer: 5ЈGGACACAGAAAAGTAATAG-GAGAG3Ј; 3Јprimer: 5ЈGATCAGGATGGTAATTCCCGTT3Ј; internal primer: 5Ј TTTTCATCATTTAAGCAGGTTATC-CATT3Ј. The FcεRI ␥ chain primers were: 5Ј primer: 5Ј CCAGCAGTGGTCTTGCTCTCTTAC 3Ј; 3Јprimer: 5ЈGCAT-GCAGGCATATGTGATGCC3Ј. PCR was carried out as described previously (23) .
Southern blot analysis
Amplified products were blotted on Hybond N membrane using standard methods (31) . Oligonucleotide probes were labeled with 3-deoxy digoxigenin-labeled ATP using terminal transferase. Hybridization was carried out as recommended by the supplier (Boehringer, Mannheim, Germany).
Cytospin preparations
Cytospin slides were prepared from BAL or peripheral blood PMNs, fixed in 4% paraformaldehyde for 20 min at room temperature and washed with 0.05M Tris-HCl-buffered isotonic saline, pH.7.6 (TBS). After drying, the slides were stored at Ϫ20°C before immunocytochemistry or in situ hybridization.
In situ hybridization
The vector containing the FcεRI␣ chain cDNA was linearized with the appropriate enzymes and transcribed with [␣ 35 S]UTP to generate sense and antisense riboprobes as recommended by the supplier (Promega, Madison, Wis.). Cytospin preparations were first permeabilized by immersion in 0.3% Triton X-100 in PBS for 10 min, followed by exposure to proteinase K (1 g/ml in 20 mM Tris-HCL and 1 mM EDTA, pH 7.2) for 30 min at 37°C. The slides were prehybridized with 50% formamide, tRNA, Denhardt's in 2ϫ SSC for 15 min at 42°C. Hybridization was performed with [␣- 35 S] UTP-labeled riboprobes (either antisense or sense) for 16 h at 42°C. Posthybridization washings were done with SSC solutions (4ϫ SSC and 0.1ϫ SSC), followed by ribonuclease A treatment to remove unhybridized single-stranded RNA. The preparations were dehydrated, immersed in emulsion, and subjected to autoradiography for 18 days. The slides were developed and subsequently counterstained with hematoxylin. As negative control, sections were hybridized with the sense probe or pretreated with RNAse before hybridization with the antisense probe.
Flow cytometry analysis
Samples of 10
5 PMNs in 100 l of PBS/5% FCS were incubated for 30 min on ice with mAb15-1, CRA2, or mAb control (final concentration 10 g/ml) in the presence of 2 mg/ml of affinity-purified human IgG to block the nonspe- To inhibit anti-FcεRI ␣ chain mAb15-1 binding to the PMNs, 10 5 cells in 100 l of PBS/5% FCS were preincubated for 1 h at 4°C with IgE-Fc (10 g/ml) with gentle agitation. Cells were then washed and incubated with a saturating concentration of mAb15-1 (10 g/ml) for 1 h at 4°C. After washing, cells were incubated with FITC-conjugated antimouse IgG for 30 min, washed, and analyzed as described above.
Inhibition of IgE-Fc fragment binding to PMNs by mAb15-1
To inhibit IgE-Fc Fragment binding to the PMNs, 10 5 cells in 100 l of PBS/5% FCS were preincubated for 1 h at 4°C with mAb15-1 or control mAb at (50 g/ml) with gentle agitation. Cells were then washed and incubated with a saturating concentration of biotin-conjugated IgE-Fc fragment (BIgE-Fc, 10 g/ml) for 1 h at 4°C. After wash, cells were incubated with extravidin-FITC for 30 min, washed and analyzed as described above.
Immunoprecipitation and Western blot analysis
For protein extraction, highly purified PMNs were lysed for 30 min at 4°C in Nonidet P-40 lysis buffer supplemented with a mixture of protease inhibitors (2 mM sodium orthovanadate, 1 mM phenyl-methylsulfonylfluoride, 10 g/ml leupeptin, 0.15 units/ml aprotinin, 1 g/ml pepstatin A) and centrifuged for 20 min to remove nuclei. Cell lysates were sequentially incubated with or without IgE Fc fragment for 16 h at 4°C in a rotating mixer, followed by protein G Sepharose-coated beads conjugated with goat anti-human IgE for 2 h at 4°C. Beads were pelleted by centrifugation and washed three times with the wash buffer (PBS/1%Nonidet P-40). For immunoblotting, samples were separated on SDSpolyacrylamide gel (13%) and electrotransferred onto polyvinylidene membrane (Millipore, Missisauga, Ontario). The membrane was blocked at room temperature for 1 h in blocking solution (10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 005% Tween-20, and 1% BSA). Membrane was incubated with anti-FcεRI␣ chain mAb15-1 (1 g/ml) at room temperature for 2 h, followed by biotin-conjugated horse anti-mouse IgG and streptavidin alkaline phosphatase. The blots were developed by enhanced chemiluminescence as recommended by the supplier (Boehringer).
Immunocytochemistry
Cytopreparations of purified PMNs from asthmatic subjects or normal controls were washed in TBS, saturated with blocking buffer (10% human normal serum, 10% normal goat serum) for 15 min at room temperature, and incubated with mAb15-1 or isotype control mAb both at 10 g/ml overnight at 4°C. After washing three times with TBS, the cytopreparations were incubated with rabbit anti-mouse IgG (1:60) for 45 min, followed by APAAP for 1 h at room temperature. After washing with TBS, the slides were developed using fast red substrate, followed by counterstaining in hematoxylin.
For ␤ chain immunodetection, cytopreparation slides were saturated with blocking buffer for 15 min, washed, and incubated with affinity-purified rabbit polyclonal anti-FcεRI␤ chain (5 g/ml) or normal rabbit serum (1:200) overnight at 4°C. After washing, biotinylated swine anti-rabbit IgG (1:200) was added for 30 min at 37°C, followed by incubation with streptavidin-conjugated alkaline phosphatase (1:200) for 1 h at room temperature; then the slides were developed using fast red substrate.
Double immunocytochemistry
To colocalize elastase and the FcεRI␤ chain, double immunohistochemistry was performed. After blocking steep, BAL slides were preincubated simultaneously with affinity-purified rabbit polyclonal anti FcεRI ␤ chain (5 g/ml) and antielastase mAb (1:100) for 2 h at room temperature. After washing, slides were incubated with biotin-labeled horse anti-mouse IgG (1:100) in the dark for 1 h at room temperature, then with streptavidin-conjugated alkaline phosphatase and FITC-conjugated F(ab)Ј 2 swine anti-rabbit Ig (1:200) for 45 min at room temperature. After visualization with fast red, the cytopreparations were washed and counterstained with hematoxylin. Normal rabbit serum (1:200) and mouse irrelevant IgG1 mAb (1:100) were used as negative controls. These slides were visualized with a Zeiss Axiophot fluorescence microscope (Carl Zeiss, Ltd., Welwyn Garden City, U.K).
PMNs stimulation
Freshly isolated PMNs (2ϫ10 6 /ml) were incubated at 37°C in humidified 5% CO 2 in RPMI 1640 medium supplemented with 10% heat-inactivated FCS and antibiotics for 2 h at 37°C with either mAb15-1 or isotype control IgG1 mAb at a final concentration of (10 g/ml). Cross-linking was then performed by adding goat anti-mouse IgG (Fab)Ј 2 (20 g/ml) and cells were incubated for another 16 h. Experiments were also performed with mAb15-1, isotype control mAb, and goat anti-mouse Ig (Fab)Ј 2 alone as negative controls. As positive control, the same PMN preparation were stimulated for 18 h with recombinant GM-CSF at 10 ng/ml. After culture, supernatants were removed, clarified by centrifugation, and stored at Ϫ80°C until analysis.
IL-8 quantification
Immunoreactive IL-8 was quantitated using dual antibody enzyme-linked immunosorbent assay kit obtained from R&D Systems (Minneapolis, Minn.) according to the manufacturer's protocol. The sensitivity limit of these kits is 10 pg/ml.
Statistics
Data are presented as mean Ϯ sd. Analysis of difference between FcεRI ␣ chain expression in PMNs from asthmatic subjects and normal controls was performed using the Mann Whitney U test. All other differences were determined using analysis of variance with post hoc Fisher's least significant difference test.
RESULTS
Detection of mRNA encoding FcRI ␣, ␤, and ␥ subunits
To determine whether human PMNs express FcεRI, the total RNA extracted from PMNs of asthmatic subjects and controls was probed with cDNA encoding for the FcεRI␣ chain. A specific signal at 1.2 kb was detected in all PMNs RNA preparations from asthmatic subjects with variable intensity according to individual donors (Fig. 1A, lanes 2, 3, 5 , 7, and 9). A positive signal was observed in eosinophils from asthmatic subjects (Fig. 1A, lanes 6 and 12) and in eosinophil differentiated HL-60 cells used as positive control (Fig. 1A, lanes 4 and 10) , but not in the undifferentiated HL-60 cells (Fig. 1A, lanes 1 and  11) . These results agree with the variable levels of FcεRI␣ chain expression observed in monocytes (22) , eosinophils (23) , and platelets (25) . Using RT-PCR and Southern blot analysis, FcεRI␣ chain mRNA expression was also detected in PMNs from asthmatic subjects and the eosinophil differentiated HL-60 cells (Fig. 4B, lanes 2-4, 6 ), but not in PMNs from normal control (Fig. 1B, lane 5) .
To investigate the nature of the FcεRI subunits in PMNs, the ␤ chain mRNA expression in highly purified PMNs was analyzed by RT-PCR and Southern blot analysis. A specific band of the expected size (446 bp) was detected in PMNs from asthmatic subjects and eosinophil differentiated HL-60 cells (Fig. 1B, lanes  2-4, 6 ). The expression of ␥ chain mRNA was detected by RT-PCR in all PMN preparations from asthmatic subjects and in normal controls (Fig. 1C) . Two amplified products of FcεRI␥ were detected: one was of the predicted size at 338 bp and one was 100 bp smaller, which may correspond to a splice variant lacking the second transmembrane region coding exon (32) .
Localization of FcRI␣ chain mRNA to PMNs by in situ hybridization
To ascertain that PMNs could express the FcεRI␣ chain, we performed in situ hybridization on PMN preparations from asthmatic subjects and normal controls. In Fig. 2A, B , PMNs from asthmatic subjects show a positive signal with the 35 S-labeled antisense FcεRI␣ chain riboprobe. No cells were labeled when incubated with the sense riboprobe (Fig. 2C) . and eosinophil differentiated HL60 cell line (lane 6). RT-PCR was performed with specific primers to ␣, ␤ and the specificity of the amplified fragments was confirmed by Southern blot analysis using an internal nested primer. C) RT-PCR analysis of FcεRI␥ chain expression on peripheral blood PMNs. All RNA preparations tested showed ␥ specific amplified fragment. ␤-Actin was used as control.
Surface expression of FcRI on human PMNs from asthmatic subjects
To determine whether peripheral blood PMNs express the FcεRI receptor on the cell surface, purified cells from 18 atopic asthmatic subjects and 18 normal controls were analyzed by flow cytometry for the expression of FcεRI␣ chain. As shown in Fig. 3A , CD16-positive PMNs from an asthmatic patient were expressed on their surface FcεRI␣ chain when assessed by mAb15-1 with mean percentage of positivity 88% (mean log fluorescence intensities of 5.5-fold over control mAb). The surface FcεRI expression was confirmed in all subjects with asthma. In every case, FcεRI expression was detectable with a mean percentage of positive cells 38 Ϯ 30% (mean log fluorescence intensity 3.2Ϯ2-fold greater than the negative control mAb, nϭ18, Fig. 3C ). However, FcεRI surface expression was not observed in freshly isolated PMNs from normal controls (nϭ18) as described previously (16; Fig. 3B, C) . Surface expression of the FcεRI␣ chain was detected in the neutrophil differentiated human cell line HL-60 (data not shown). Taken together, these data indicate that human PMNs from asthmatic subjects but not from normal controls express the mRNA and the membrane-bound FcεRI receptor.
Inhibition of IgE Fc fragments binding to PMNs by mAb15-1
We performed an inhibition binding study to determine whether anti-FcεRI␣ chain mAb15-1 could inhibit the binding of biotin-labeled chimeric IgE Fc fragments (BIgE-Fc) to human PMNs. A subpopulation of PMNs from an asthmatic patient expressing FcεRI receptor (60.7% positivity, Fig. 4A ), was also able to bind the BhIgE-Fc (78.3% positivity, Fig. 4B ). The specificity of IgE binding was confirmed by the fact that it could be inhibited by preincubation of PMNs with the mAb15-1 (Fig. 4B) or CRA-2 (data not shown). Similar results were obtained in PMNs from additional subjects with a mean percentage of inhibition 67 Ϯ 5.9% (nϭ3). In contrast to anti-FcεRI␣ chain mAb15-1, IgG1 isotype control has no effect on the binding of BIgE-Fc to PMNs (Fig. 4D) . Conversely, the binding of mAb15-1 was significantly inhibited by preincubation with unlabeled IgE-Fc (Fig. 4A) but not with a high dose of human IgG (2 mg/ml) (Fig. 4C) . These results demonstrate clearly that human IgE binds mainly to the cell surface of human PMNs via the FcεRI.
To further support this notion, we identified the FcεRI␣ chain from PMNs total protein extracts using immunoprecipitation with IgE Fc fragment and antiIgE, followed by Western blot analysis using mAb15-1. A band of the expected molecular size (ϳ46 kDa) corresponding to the FcεRI␣ chain was detected on PMNs and peripheral blood mononuclear cells used as positive control (Fig. 5, lanes 1-3 and 4, respectively) . No band could be detected in PMNs from normal control or when the Western blot was performed with mAb15-1 without prior IgE immunoprecipitation (Fig.  5, lanes 5, 6) .
Detection of FcRI␣ and ␤ subunits in peripheral blood and BAL PMNs by immunocytochemistry
To investigate the protein expression of the FcεRI subunits on PMNs, immunocytochemistry was performed with anti-FcεRI␣ chain mAb15-1 and polyclonal anti-␤ chain. Figure 6A , C shows a specific staining with mAb15-1 and polyclonal anti-␤ chain in peripheral blood PMNs from an asthmatic subject. Substitution of the primary antibody with irrelevant mouse IgG1 or normal rabbit serum eliminated the immunostaining confirming the specificity of the reaction (Fig. 6B, D) . In addition, the expression of FcεRI␣ chain immunoreactivity in blood PMNs was significantly higher in asthmatic subjects compared to normal controls (data not shown).
Bronchoalveolar lavage (BAL) cytospins from asthmatic subjects were also analyzed using immunocytochemistry with anti-FcεRI␣ and ␤ chain antibodies. Cells with multilobed nuclei exhibit positive immunoreactivity for the FcεRI␣ and ␤ chains (red staining) (Fig. 6E, G) . Other cell types in the BAL that show immunoreactivity to mAb15-1 and polyclonal anti-␤ chain include macrophages, previously reported to express FcεRI (26) . However, no signal was detected 1 to 3) , peripheral blood mononuclear cells (PBMC) used as positive control (lane4), but not in PMNs from normal control (lane5). Cell lysate was first immunoprecipitated with IgE Fc fragment (lanes 1 to 5) or without IgE Fc fragment (lane 6) and followed by protein G Sepharose-coated beads conjugated with goat anti-human IgE. The eluate was separated by SDS-PAGE (13%) and transferred to membrane. The membrane was incubated with mAb15-1, followed by biotin-conjugated horse anti-mouse Ig and streptavidin alkaline phosphatase.
with isotype control (Fig. 6F, H) . The neutrophil phenotype nature of the positively stained BAL cells was confirmed by double immunocytochemistry using antihuman elastase, a specific marker for PMNs, and polyclonal anti-␤ chain (Fig. 6I, J) .
FcRI-mediated IL-8 release from human PMNs
IL-8 production and release is one feature of the allergic process (33) . To verify whether the engagement of FcεRI expressed in human PMNs induce the release of IL-8, peripheral blood PMNs from asthmatic subjects were incubated with mAb15-1(10 g/ml) and cross-linked with anti-mouse IgG(Fab)Ј 2 . The IL-8 release was evaluated in culture medium after 18 h. As shown in Fig. 7 , cross-linking of FcεRI induced significant release of IL-8 compared to mAb control. Indeed, the levels of IL-8 released in the external milieu was almost 10-fold increased in mAb15-1-stimulated PMNs from asthmatic subjects when compared with control mAb (493Ϯ87pg/ml vs. 47Ϯ18pg/ml, respectively,  PϽ0.001, nϭ3) . Furthermore, a significant amount of IL-8 was detected in external medium when the same preparation of PMNs was incubated with GM-CSF used as positive control (data not shown). Therefore, these data indicate that PMN activation via FcεRI leads to the release of IL-8.
DISCUSSION
Although the expression of FcεRI has been shown on inflammatory cells, its expression on PMNs had not been reported before. In this study, we have shown the surface expression of FcεRI on peripheral blood PMNs obtained from asthmatic subjects and demonstrated that these cells express the mRNA for all three subunits. Most important, human IgE mainly bind to the cell surface of PMNs from asthmatic subjects via FcεRI, and the engagement of this receptor is involved in the release of IL-8 from PMNs. The finding that PMNs from asthmatic subjects can be activated through FcεRI engagement suggests that these cells may have an effect at the site of inflammation through the release of chemokines.
Here we provide several lines of evidence to indicate that PMNs from asthmatic subjects express the FcεRI receptor at the mRNA and protein level, first by Northern blot and RT-PCR using highly purified PMN preparations (purity more than 98%) and by using in situ hybridization to rule out the possibility of contamination and to colocalize the mRNA of FcεRI ␣ chain at the cellular level. We showed clearly the presence of positive signal in a subpopulation of PMN preparation from asthmatic subjects but not in normal controls. This indicates that the expression of FcεRI␣ mRNA is not constitutive, but rather under regulatory control, and it is quite possible that cellular microenvironment such as in allergic asthma may induce FcεRI expression. Second, FACS analysis using anti-FcεRI mAbs, mAb15-1, and CRA-2, reagents previously shown to bind specifically to transfectants expressing FcεRI receptor (20, 27) , bound in a similar fashion to PMNs. Short-term (1 h) preincubation with mAb15-1 or CRA-2 significantly inhibited (ϳ70%) the IgE binding to PMNs, which is similar to what has been described for eosinophils and platelets (23, 34) . Conversely, IgE Fc fragment inhibited completely the binding of mAb15-1 to PMNs. Third, immunoprecipitation and Western blot analysis confirmed the presence of FcεRI␣ chain on PMNs. Consistent with membrane surface expression observed with FACS analysis, peripheral blood and BAL PMNs from asthmatic subjects also exhibit positive immunoreactivity for the ␣ and ␤ chains; double immunocytochemistry colocalized FcεRI␤ chain immunoreactivity to elastase-positive cells in BAL.
Although surface expression of FcεRI␣ was detected on PMNs obtained from the majority of asthmatic subjects, the expression was widely heterogeneous among individual donors, as described previously on other inflammatory cells (22) (23) (24) (25) . Moreover, a significant difference was observed between the level of FcεRI␣ surface expression and FcεRI immunopositive PMNs detected by immunocytochemistry, which detect both the surface and intracellular stored protein (data not shown). Similar observations have been reported in epidermal Langerhans cells (35) and eosinophils (23, 36) . Furthermore, in contrast to asthmatic patients, PMNs isolated from normal controls showed no surface expression (16) and immunoreactivity for FcεRI␣. The lack of FcεRI␣ chain surface expression on PMNs from normal controls may be explained by several possibilities. Previous in vivo and in vitro studies have shown that surface expression of many Fc receptors on human PMNs are up-regulated or induced after treatment with cytokines. In particular, the Th-2 cytokines, GM-CSF, and IL-4 have been shown to induce the surface expression of CD23/FcεRII (16) and CD11b/CD18 (37) on human PMNs and to up-regulate the FcεRI␣ chain mRNA expression in human eosinophils (38) . In accordance with this, GM-CSF and IL-4 receptors have been demonstrated on human PMNs (39, 40) . As such, one may speculate that factors highly expressed in allergic asthma such as Th-2 cytokines may induce the FcεRI␣ chain receptor by, to be determined, mechanism(s).
Recently, lack of FcεRI␣ surface expression has been also shown in PMNs isolated from human FcεRI␣ chain transgenic mice (41, 42) , which is in contrast to our observation in asthmatic subjects but in accordance with normal controls. The basis for the difference of expression between FcεRI␣ transgenic mice and human is not known, and it is quite possible that the cellular microenvironment is one critical factor to explain this difference. To address this issue, it will be worthwhile to investigate the FcεRI expression in PMNs in immunized and challenged human FcεRI␣ transgenic mice that may mimic, in part, the atopic asthmatic state. Further studies are under way to understand the mechanism underlying the regulation of FcεRI expression in PMNs.
Human FcεRI expression on the cell surface is known to require at least the ␣ and ␥ chains (43, 44) . The ability of the ␥ chain to allow surface expression of the FcεRI␣ chain is analogous to the role of the chains in the expression of the TCR-CD3 complex, although the molecular mechanism of the FcεRI assembly is still unclear. Both the FcεRI and ␥ chains are highly conserved at the transmembrane portions, which are suggested to be important for proper assembly of the FcεRI receptor complex (43, 44) . We have demonstrated here the expression of mRNA for all three FcεRI chains, indicating that FcεRI on PMNs may be a multimeric complex composed of the same polypeptides as that of the FcεRI of mast cells and basophils (17) . Furthermore, we have showed ␣ and ␤ immunoreactivity in blood and BAL PMNs. Since we did not identify all three chains on individual cells, surface expression of functional FcεRI in the absence of the ␤ chain, as reported for Langerhans cells, monocytes, and dendritic cells (20 -21, 23) , cannot be ruled out. The role of the ␤ chain has been suggested by the finding that it is also associated with the Fc␥RIII, which like the FcεRI contribute to the initiation of allergic reactions (45) . A correlation of mutations on the FcεRI␤ chain gene with atopic dermatitis has also been reported (46, 47) . More recently, analysis of FcεRI and Fc␥RIII-dependent responses in mouse models provides genetic evidence that ␤ chain functions as an amplifier of early and late mast cell responses and in vivo anaphylactic responses (42) .
Although PMNs have been largely neglected as immune cells due to their apparent limited capacity to carry out immune functions, recent data show that PMNs can express MHC class II molecules both in vivo and in vitro (48, 49) and produce cytokines that can stimulate both cellular and humoral immunity (14) . In allergic inflammation, the surface expression of FcεRI by human PMNs may be involved in IgE-dependent allergen presentation similar to dendritic cells (23) , the release of neutrophil-specific chemoattractants such as LTB4 (13) , cytokines, and/or chemokines as reported in mast cells and basophils (17) (18) (19) . We found that FcεRI engagement induces the release of IL-8. IL-8 has been shown to have chemotactic activity for activated T lymphocytes, eosinophils, and basophils and to enhance the expression of integrins in monocytes as well their adherence to endothelial cells (33) . Our finding suggests that the significant contribution of human PMNs via IgE-dependent activation of FcεRI may be in attracting other inflammatory cells that more directly cause the airway responses. Enhancement of eosinophils and monocytes accumulation are such examples, but it seems reasonable to suggest that neutrophilic inflammation might contribute to the T lymphocyte emigration (50) . This indicates that PMNs may fulfill immunoregulatory functions by contributing to the local recruitment of inflammatory cells. Experiments are under way to fully characterize the functions of FcεRI on PMNs.
Neutrophilic airway inflammation has been described in subjects with asthma exacerbation (51) . PMNs recruitment may result from an inflammatory cascade, which may include viral infection (51) . Moreover, PMNs are a potential source of variety of proinflammatory mediators, proteases, and cytotoxic molecules that can be toxic to bronchial structures (52) (53) (54) . The activation of PMNs could be a potentially relevant destructive mechanism of the epithelial lining of the airway in asthma, possibly resulting in increased bronchial hyperresponsiveness. It is tempting to speculate that IgE-dependent activation of PMNs in some asthmatic subjects may play a role in the exacerbation of asthma.
In conclusion, our study presents the first evidence that human PMNs can express functional FcεRI on their surface and raises the possibility that these cells may play an important role in asthma via an IgEdependent mechanism.
